Snapshot from Aug 10, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Capricor Securities Fraud Class Action
Regulatory class action

Capricor Securities Fraud Class Action

Analysis based on 7 articles · First reported Aug 03, 2026 · Last updated Aug 08, 2026

Sentiment
-30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit adds legal and regulatory uncertainty for Paragon Therapeutics, potentially pressuring its stock price and raising concerns about the approval prospects of its lead candidate Deramiocel. The allegations of undisclosed changes to the statistical analysis plan could undermine investor confidence in the company's clinical data integrity and regulatory strategy.

Biotechnology Pharmaceuticals
Event Summary

Rosen Law Firm, a global investor rights law firm, announced a class action lawsuit on behalf of purchasers of Paragon Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements and/or failed to disclose that it adopted changes to the pre-specified statistical analysis plan for its cell therapy Deramiocel without prior FDA agreement, creating a significant risk that the FDA would not find substantial evidence of effectiveness, thereby jeopardizing regulatory approval for the treatment of Duchenne muscular dystrophy. Investors who purchased during the class period may be entitled to compensation, and the deadline to move for lead plaintiff is September 28, 2026.

Key Actions
90 Rosen Law Firm filed class action lawsuit Paragon Therapeutics
Entities Involved
priv
Paragon Therapeutics
Capricor is the defendant in the securities class action, facing allegations of misleading investors about its clinical trial analysis and FDA approval risks for Deramiocel. The lawsuit could lead to financial damages and reputational harm, and may negatively affect its stock price and regulatory outlook.
Importance 100.0 Sentiment -40.0
priv
Rosen Law Firm
Rosen Law Firm is the plaintiff's counsel leading the class action, seeking to represent investors. The firm benefits from the case through potential legal fees and enhanced reputation in securities litigation.
Importance 80.0 Sentiment 20.0
govactor
United States — Food and Drug Administration
The FDA is central to the allegations, as the lawsuit claims Capricor changed its statistical analysis plan without FDA agreement, affecting the regulatory review of Deramiocel. The FDA's decisions will be critical to the outcome of the case and the drug's approval.
Importance 70.0 Sentiment 0.0
per
Lawrence Rosen
Lawrence Rosen is the founding partner of Rosen Law Firm and is involved in the class action as counsel. His role is to represent the investor class and pursue the litigation.
Importance 30.0 Sentiment 10.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm handling the case, providing contact for investors to join the class action. His role is to manage the litigation and communicate with potential class members.
Importance 30.0 Sentiment 10.0
Relationships
Paragon Therapeutics related ↔ United States — Food and Drug Administration
Rosen Law Firm related ↔ United States — Food and Drug Administration
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
United States — Food and Drug Administration related ↔ Lawrence Rosen
United States — Food and Drug Administration related ↔ Philip Kim
Lawrence Rosen managing partner ↔ Philip Kim Lawrence Rosen is the founder and managing partner of Rosen Law Firm, where Philip Kim is a partner, and they actively c
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.